Machine-learning aided in situ drug sensitivity screening predicts treatment outcomes in ovarian PDX tumors-Reference-Cited by-同舟云学术

Machine-learning aided in situ drug sensitivity screening predicts treatment outcomes in ovarian PDX tumors

Published:2022-07 Issue: Volume:21 Page:101427
ISSN:1936-5233
Container-title:Translational Oncology
language:en
Short-container-title:Translational Oncology

Author:

Cotler Max J.^ORCID,Ramadi Khalil B.^ORCID,Hou Xiaonan,Christodoulopoulos Elena,Ahn Sebastian,Bashyam Ashvin^ORCID,Ding Huiming,Larson Melissa,Oberg Ann L.^ORCID,Whittaker Charles^ORCID,Jonas Oliver,Kaufmann Scott H.^ORCID,Weroha S. John,Cima Michael J.^ORCID

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference49 articles.

1. Molecular landscape and actionable alterations in a genomically guided cancer clinical trial: National Cancer Institute molecular analysis for therapy choice (NCI-MATCH);Flaherty;J. Clin. Oncol.,2020

2. Improved overall survival in melanoma with combined dabrafenib and trametinib;Robert;N. Engl. J. Med.,2015

3. Dabrafenib and trametinib in patients with tumors with BRAF V600E mutations: results of the NCI-MATCH trial subprotocol H;Salama;J. Clin. Oncol.,2020

4. Estimation of the percentage of US patients with cancer who benefit from genome-driven oncology;Marquart;JAMA Oncol.,2018

5. Estimation of the percentage of US patients with cancer who are eligible for immune checkpoint inhibitor drugs;Haslam;JAMA Netw. Open,2020

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Leveraging preclinical models of metastatic breast cancer;Biochimica et Biophysica Acta (BBA) - Reviews on Cancer;2024-09

2. Harnessing machine learning potential for personalised drug design and overcoming drug resistance;Journal of Drug Targeting;2024-06-13

3. New Drug Discovery;Multidisciplinary Applications of Natural Science for Drug Discovery and Integrative Medicine;2023-06-16